

April 1, 2024
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice of Personnel Changes at SymBio Pharma USA, Inc.

TOKYO, April 1, 2024 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) today announced the appointment of John Houghton as CEO and President of SymBio Pharma USA, Inc. (established in May 2016; wholly owned US subsidiary, “SPU”), effective April 1, 2024, replacing Stephane Berthier, who was previously CEO and President of SPU. With this appointment, SPU will develop its full-scale operations with a mission to drive the development of the intravenous formulation of brincidofovir (“IV BCV”) toward commercialization in Europe, the U.S., Japan and the UK.

Statement from Mr. John Houghton: “I am deeply honored to join SymBio at this pivotal juncture in their journey, as they aim to emerge as a leading global specialty biopharmaceutical company committed to delivering hope to patients in need. Collaborating with SymBio’s experienced professionals, I am convinced that we can elevate the company to unprecedented heights. Together, we will advance SymBio’s mission of identifying, developing, and delivering innovative therapeutic solutions to patients suffering in underserved therapeutic areas, making meaningful contributions to healthcare.”

Statement from Fuminori Yoshida, President and CEO of SymBio: “I am pleased to announce the appointment of Mr. John Houghton as the new CEO and President of SymBio Pharma USA. John is an accomplished industry leader with more than 30 years of experience both with major pharmaceutical companies as well as start-up biotech companies, including leading one to a public listing in the US. With his vast experience in building global business and proven leadership skills, John will undoubtedly bring value and drive to the growth and expansion of our global business. I am confident that under his leadership, SymBio Pharma USA will continue to thrive and achieve key milestones in this transformative phase of the company.”

SymBio Pharma USA, Inc. (summary)

Name	SymBio Pharma USA, Inc. (SPU)
Address	Durham, North Carolina, USA
Representative	John Houghton
Establishment Date	May 10, 2016
Shareholders	A 100% subsidiary of SymBio Pharmaceuticals Limited
Business Activities	Research and development of pharmaceutical products

1. Name and Title

Name	Title
John Houghton	CEO and President of SPU

2. Date of appointment: April 1, 2024

3. Profile of the newly appointed President and CEO of SPU

1987	Sales Rep., CYANAMID OF GREAT BRITAIN Ltd., Gosport, UK
1992	Marketing Manager – Respiratory & Business Planning, RHONE-POULENC RORER Ltd., West Malling and Eastbourne, UK
2000	Disease Group Head, New Products Commercialization, Global Marketing & Medical, AVENTIS, Bridgewater, N.J.
2005	Vice President, Global Sales & Marketing, STRYKER BIOTECH, Hopkinton, Massachusetts, USA
2007	President & CEO and Board Director, CORMEDIX, INC., Bridgewater, New Jersey, USA (A public pharmaceutical company)
2012	President & CEO, Acting CFO and Board Director, NEPHROS, INC., River Edge, New Jersey, USA (A public Medical Device company)
2015	Global Franchise Head – Roxadustat, ASTRAZENECA, Gaithersburg, Maryland, USA (A public pharmaceutical company)
2021	President & CEO and Board Director, AVOTRES, INC. Cedar Knolls, New Jersey, USA (A private Biotech company)
2024	April 1: Join SymBio Pharma USA, Inc.
	BSc (Hons) Sport Science, Liverpool John Moores University (Liverpool, England) GCE ‘A’ Levels: Physics; Mathematics, North Notts College of Further Education (Worksop, England)

About SymBio Pharmaceuticals Limited.

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, representative: John Houghton). The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125